A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Novo Nordisk

Status and phase

Completed

Phase 4

Conditions

Obesity

Treatments

Drug: Semaglutide

Drug: Phentermine/Topiramate

Drug: Orlistat

Drug: Naltrexone/Bupropion

Drug: Liraglutide

Study type

Interventional

Funder types

Industry

Identifiers

NCT05579249

U1111-1263-7301 (Other Identifier)

NN9536-4741

Details and patient eligibility

About

The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).

Enrollment

500 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Body mass index (BMI) greater than equal to 30.0 kilogram per meter square (kg/m^2).
Employed at randomisation by one of the selected employers and expecting to be so for the duration of the study.

Exclusion criteria

Known or suspected hypersensitivity or contraindications to Wegovy or related products according to the label.
Known or suspected hypersensitivity or contraindications to all of the other Anti-Obesity Medications (AOMs) for chronic weight management (Xenical, Qsymia, Contrave, and Saxenda) or related products according to the labels.
Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
History of type 1 or type 2 diabetes mellitus.
Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might jeopardise participant's safety or compliance with protocol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

500 participants in 2 patient groups

Semaglutide

Experimental group

Description:

Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management.

Treatment:

Drug: Semaglutide

Other anti-obesity medication

Active Comparator group